Ajooni Biotech Limited AI Stock Analysis
Want to see IN:AJOONI full AI Analyst Report?
Ajooni Biotech Limited (AJOONI) AI Stock Analysis
Ajooni Biotech Limited
(NSE:AJOONI)
The overall score reflects a company with strong top-line growth and an improving, modestly leveraged balance sheet offset by structurally weak cash generation and thin, volatile margins, while neutral-to-weak technicals and a broadly middle-of-the-road valuation provide neither a strong upside nor downside signal.
Ajooni Biotech Limited (AJOONI) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 539.12M
- Dividend Yield
- ―
- Average Volume (3M)
- 403.46K
- Price to Earnings (P/E)
- 14.1
- Beta (1Y)
- 0.92
- Revenue Growth
- 78.39%
- EPS Growth
- 15.76%
- Country
- India
- Employees
- 182
- Sector
- General
- Sector Strength
- 55
- Industry
- Packaged Foods
Ajooni Biotech Limited Business Overview & Revenue Model
Company Description
Founded in 2010, Ajooni Biotech Limited is an Indian enterprise primarily engaged in the production and distribution of animal nutrition products. Headquartered in Mohali, India, the company's offerings encompass specialized cattle feeds and various...
How the Company Makes Money
Ajooni Biotech Limited primarily makes money by selling animal health and nutrition products (and related livestock/poultry-focused inputs) through its sales and distribution channels to customers in the animal husbandry ecosystem (e.g., farms, distr...
Ajooni Biotech Limited Financial Statement Overview
Summary
Strong revenue growth and a strengthening, low-leverage balance sheet support a solid score, but thin and volatile margins and persistently weak, negative cash flows materially constrain the financial quality.
Income Statement
73PositiveBalance Sheet
78PositiveCash Flow
28Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.15B | 1.82B | 1.15B | 801.15M | 744.88M | 740.38M |
| Gross Profit | 303.98M | 276.71M | 138.13M | 97.65M | 87.45M | 100.24M |
| EBITDA | 76.80M | 62.56M | 57.57M | 44.27M | 30.60M | 31.12M |
| Net Income | 39.59M | 43.22M | 32.38M | 21.61M | 11.25M | 10.49M |
Balance Sheet | ||||||
| Total Assets | 1.25B | 1.20B | 950.51M | 475.20M | 587.31M | 290.18M |
| Cash, Cash Equivalents and Short-Term Investments | 3.74M | 4.19M | 68.30M | 4.30M | 4.93M | 573.86K |
| Total Debt | 269.11M | 177.63M | 19.40M | 21.68M | 51.77M | 53.50M |
| Total Liabilities | 332.86M | 291.74M | 69.72M | 48.12M | 170.62M | 126.35M |
| Stockholders Equity | 916.23M | 911.91M | 880.79M | 427.08M | 416.69M | 163.82M |
Cash Flow | ||||||
| Free Cash Flow | 18.31M | -232.32M | -192.16M | -95.54M | -84.39M | 15.60M |
| Operating Cash Flow | 135.46M | -52.03M | -171.84M | -39.52M | -55.79M | 36.84M |
| Investing Cash Flow | -122.77M | -170.31M | -171.34M | 76.37M | -158.24M | -18.97M |
| Financing Cash Flow | 71.88M | 158.23M | 248.26M | -35.66M | 216.55M | -19.73M |
Ajooni Biotech Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AJOONI, the sentiment is Neutral. The current price of 3.13 is above the 20-day moving average (MA) of 2.93, below the 50-day MA of 3.14, and below the 200-day MA of 3.88, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 58.25 is Neutral, neither overbought nor oversold. The STOCH value of 38.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:AJOONI.
Ajooni Biotech Limited Peers Comparison
Overall Rating
IN:AVANTIFEED71Outperform
IN:SKMEGGPROD70Outperform
IN:PARAGMILK63Neutral
IN:MUKKA61Neutral
IN:AJOONI60Neutral
IN:MKPL47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 71Outperform | INR 101.76B | 22.03 | ― | 1.34% | 8.99% | -27.78% | |
| 70Outperform | INR 12.12B | 11.59 | ― | 0.54% | 21.31% | 89.98% | |
| 63Neutral | INR 41.56B | 32.80 | ― | 0.33% | 13.13% | -10.08% | |
| 61Neutral | INR 7.97B | 10.04 | ― | ― | 84.77% | 67.73% | |
| 60Neutral | INR 567.29M | 14.10 | ― | ― | 78.39% | 15.76% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 47Neutral | INR 1.46B | 31.14 | ― | ― | 17.76% | -50.16% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:AJOONI | Ajooni Biotech Limited | 3.13 | -1.90 | -37.77% | |
| IN:AVANTIFEED | Avanti Feeds Limited | 746.85 | -9.23 | -1.22% | |
| IN:MKPL | M K Proteins Limited | 3.89 | -2.62 | -40.25% | |
| IN:MUKKA | Mukka Proteins Limited | 26.58 | 0.44 | 1.68% | |
| IN:PARAGMILK | Parag Milk Foods Ltd. | 331.10 | -18.98 | -5.42% | |
| IN:SKMEGGPROD | SKM Egg Products Export (India) Ltd. | 230.20 | 17.06 | 8.00% |
Ajooni Biotech Limited Corporate Events
Ajooni Biotech Confirms SEBI-Compliant Corporate Website Now Fully Functional
Ajooni Biotech Limited has notified the National Stock Exchange of India that its corporate website has been updated and is now fully functional in line with Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 13, 2026
